[SCHEDULE 13G/A] Leap Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A disclosure for Leap Therapeutics, Inc. (LPTX) This filing is a joint Schedule 13G/A by Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju reporting that, as of June 30, 2025, each Reporting Person beneficially owns 0 shares (0.0%) of Leap Therapeutics common stock (CUSIP 52187K200). The Reporting Persons state they are not a "group" and provide a Palo Alto business address for the filer. The filing incorporates a prior Joint Filing Statement by reference and is signed by Srinivas Akkaraju on behalf of the entities on August 14, 2025. The statement certifies the securities were not acquired to influence control of the issuer.

Positive

• Clear disclosure of beneficial ownership showing 0 shares and 0.0% of the class
• Explicit disclaimer that the Reporting Persons are not acting as a group, reducing ambiguity
• Incorporation of prior Joint Filing Statement for record continuity

Negative

• No material holdings reported, so the filing provides no information about investment intent or support for the issuer
• No financial metrics or transactions disclosed; filing is purely ownership confirmation

Insights

Financial Analyst

TL;DR: Reporting persons disclose zero beneficial ownership, so there is no investor stake affecting LPTX's capitalization.

The filing is straightforward: three affiliated reporting persons certify they hold no beneficial interest in Leap Therapeutics as of June 30, 2025. For market impact this is neutral because no holdings were disclosed that would alter share supply, voting outcomes, or signal a strategic investment. The explicit disclaimer of group status reduces potential ambiguity about coordinated ownership. The document is procedural and does not provide financial metrics or changes to capital structure.

Corporate Governance Expert

TL;DR: Governance implications are minimal because the filers report 0% ownership and disclaim being a group.

The Schedule 13G/A meets disclosure norms by stating ownership, address, and signing certifications. The absence of shares means no voting influence or capacity to effect corporate control from these reporting parties. The filing’s incorporation of a prior Joint Filing Statement is typical for record continuity. From a governance perspective this is a routine compliance filing with no material effect on board control or shareholder dynamics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Leap Therapeutics, Inc.

(Name of Issuer)

Common stock, $0.001 par value per share

(Title of Class of Securities)

52187K200

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52187K200

1

Names of Reporting Persons

Samsara BioCapital, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 52187K200

1

Names of Reporting Persons

Samsara BioCapital GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 52187K200

1

Names of Reporting Persons

Srinivas Akkaraju

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Leap Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: Samsara BioCapital, L.P. ("Samsara LP") Samsara BioCapital GP, LLC ("Samsara GP") Srinivas Akkaraju ("Dr. Akkaraju") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301
(c)	Citizenship: Samsara LP Delaware Samsara GP Delaware Dr. Akkaraju United States
(d)	Title of class of securities: Common stock, $0.001 par value per share
(e)	CUSIP No.: 52187K200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Samsara BioCapital, L.P.

Signature:	/s/ Srinivas Akkaraju
Name/Title:	By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:	08/14/2025

Samsara BioCapital GP, LLC

Signature:	/s/ Srinivas Akkaraju
Name/Title:	By Srinivas Akkaraju, Managing Member
Date:	08/14/2025

Srinivas Akkaraju

Signature:	/s/ Srinivas Akkaraju
Name/Title:	Srinivas Akkaraju
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Statement, dated as of April 25, 2024 (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on April 25, 2024).

FAQ

What does the Schedule 13G/A filed by Samsara BioCapital mean for LPTX?

This Schedule 13G/A states that Samsara BioCapital, its GP and Srinivas Akkaraju beneficially own 0 shares (0.0%) of Leap Therapeutics as of June 30, 2025, so there is no disclosed ownership stake affecting LPTX.

Who are the reporting persons on the LPTX Schedule 13G/A?

The reporting persons are Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju with a filer address c/o Samsara BioCapital, LLC, 628 Middlefield Road, Palo Alto, CA 94301.

Does the filing indicate these parties are coordinating on ownership of LPTX?

The Reporting Persons expressly disclaim status as a 'group', indicating they do not claim coordinated ownership under this filing.

When were the signatures on the Schedule 13G/A executed?

The Schedule 13G/A is signed by Srinivas Akkaraju on behalf of the entities and personally with signature dates of August 14, 2025.

Is there any indication the securities were acquired to influence control of Leap Therapeutics?

The filing includes a certification stating the securities were not acquired to change or influence control of the issuer.